Cantargia: Large License Deal
15 juli, 10:12
15 juli, 10:12
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded.
15 juli, 10:12
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded.
Swedbank
Rapportperioden
Swedbank
Rapportperioden
1 DAG %
Senast
Cloetta
Idag, 17:42
ABB upp och Essity ned efter rapporter
ISS
Idag, 17:35
Nordea mot strömmen efter rapport
OMX Stockholm 30
1 DAG %
Senast
2 555,63